Airdoc 鹰瞳科技 vs Shukun 数坤科技
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Airdoc 鹰瞳科技
HK-listed retinal AI for chronic-disease screening and myopia care
Visit
|
Shukun 数坤科技
Beijing imaging AI with China's most Class III approvals, by its own c...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 6.8 / 10 | 6.8 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Custom | Enterprise |
| Free tier | — | — |
| Paid from | Screening quoted; the PBM myopia device is listed at ¥13,800 | Quoted on request (hospital and distributor sales, trial by application) |
| Has API | ✗ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | — | — |
| Founded | 2015 | 2017 |
| Maker | — | — |
| Verdict | Airdoc's retinal AI has an unusually strong regulatory record: NMPA Class III approval for diabetic retinopathy in August 2020 and for retinal vein occlusion in April 2025, CE MDR certification for its fundus software, a... |
Shukun's case rests on approvals and breadth: 18 Chinese Class III certificates by its count, MDR CE marks across cardiac, stroke and other tools, PMDA approvals in Japan and three FDA 510(k) clearances, including Corona... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.